The Future of Renal Denervation in Resistant Hypertension

Current Hypertension Reports

Volumn 16, Issue 12, 2014, Pages 1-5

  Nathan, Sandeep ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Cardiovascular; Denervation; Hypertension; Resistance

Indexed keywords

ADVENTITIA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; HEART FAILURE; HUMAN; KIDNEY DENERVATION; MALIGNANT HYPERTENSION; MAXIMUM TOLERATED DOSE; MORBIDITY; RENAL ARTERY; RESISTANT HYPERTENSION; REVIEW; SENSORY NERVE; SLEEP DISORDERED BREATHING; SYMPATHECTOMY; SYMPATHETIC TONE; ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; COMPLICATION; DENERVATION; FORECASTING; HYPERTENSION; INNERVATION; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DENERVATION; FORECASTING; HUMANS; HYPERTENSION; KIDNEY;

EID: 84910107845     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0494-0     Document Type: Review

References (24)

1. Quinones MA, Greenberg BH, Kopelen HA, Koilpillai C, Limacher MC, Shindler DM, et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of left ventricular dysfunction. J Am Coll Cardiol. 2000;35(5):1237–44.
2. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42. This reviews the epidemiology of what is known regarding the incidence and prevalence of resistant hypertension.
3. Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000;13(6 Pt 2):99S–105S.
4. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Bohm M, Campese VM, et al. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62(22):2031–45. The paper summarizes the international consensus on the approach to evaluation and treatment of resistant hypertension and who would benefit from renal denervation.
5. Myat A, Redwood SR, Qureshi AC, Thackray S, Cleland JG, Bhatt DL, et al. Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications. Circ Cardiovasc Interv. 2013;6(2):184–97.
6. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R245–53.
7. Papademetriou V, Rashidi AA, Tsioufis C, Doumas M. Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. Circulation. 2014;129(13):1440–51.
8. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152(16):1501–4.
9. Froeschl M, Hadziomerovic A, Ruzicka M. Percutaneous renal sympathetic denervation: 2013 and beyond. Can J Cardiol. 2014;30(1):64–74.
10. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932–4.
11. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.
12. Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–9. This is a review of the 3-year follow-up data from the Symplicity HTN-1 proof-of-concept study.
13. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.
14. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901–9.
15. Xu J, Hering D, Sata Y, Walton A, Krum H, Esler MD, et al. Renal denervation: current implications and future perspectives. Clin Sci. 2014;126(1):41–53.
16. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. The results of the Symplicity HTN-3 trial with many supplemental data and figures about the results.
17. Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64:1071–8. This paper presents all the ABPM data including all subanalyses on heart rate and BP variability.
18. Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med. 2014;370(15):1454–7.
19. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–74. Important paper on lack of adherence documented by questionnaires and urinary analysis of drug metabolites.
20. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855–61.
21. Barbash IM, Waksman R. Sympathetic renal denervation: hypertension beyond SYMPLICITY. Cardiovascular Revascularization Medicine: Including Molecular Interventions. 2013;14(4):229–35.
22. Drexel T, Bertog SC, Vaskelyte L, Sievert S. Renal denervation. Anadolu Kardiyol Derg. 2014;14(2):186–91.
23. http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=1882200&highlight. Webpage Medtroniccom. Accessed 28 July 2014.
24. S W. Longer term safety and efficacy of catheter-based renal sympathetic denervation using a multi-electrode renal artery denervation catheter in patients with drug resistant essential hypertension: 24 month results of a first-in-human, multicenter study—EnligHTN I. Presented at EuroPCR, Paris, France; May 21–23, 2014. 2014.